PubMed Health⌕ Search

Biomedical subjects

O V Siniachenko

Publications and source records attributed to O V Siniachenko.

At least 55 records · Page 3Linked to original sources
PubMed1990

[The treatment results in patients with gouty nephropathy].

The efficacy of isolated and combined treatment of renal lesions sallopurionol (milurit), potassium orotate, azathioprin (6-mercaptopurin) was studied in 207 inpatients with primary podagra. Citrate mixtures, urinary antiseptic and hypotensive agents were used when indicated. Follow-up results from 1 to 12 years are analyzed. Prolonged systematic complex treatment of podagric nephropathy is medically and economically effective.

Absenteeism↗
PubMed1989

[Clinical aspects and treatment of primary focal segmental glomerulosclerosis and hyalinosis].

The authors studied the clinico-laboratory values and efficacy of pathogenetic treatment in 8 patients with primary segmental glomerulosclerosis and hyalinosis (PSGH). The disease is characterized by distinct disorders in the T-system immunity. Glucocorticoid treatment did not essentially effect the course of PSGH. Cyclophosphane treatment allowed to achieve essential stable clinical improvement in certain patients.

Adolescent↗
PubMed1989

[Clinico-morphologic comparisons in primary diffuse mesangio- proliferative glomerulonephritis].

Data are reported of a clinical and morphological including electron microscopical study of 132 patients with primary diffuse mesangioproliferative glomerulonephritis (DMPGN). A comparison of morphological signs using methods of non-parametric statistics revealed a complex dependence between glomerulosclerosis and sclerosis of the stroma, tubular atrophy and dystrophy; sclerosis of stroma and its cellular infiltration. Comparison of morphological aspects and clinical manifestations of DMPGN allowed to establish that development of disorders of partial functions of the kidneys has a complex genesis as evidenced by dependence of disorders on the presence and severity of glomerulosclerosis, stroma sclerosis, tubular atrophy and frequency of crescents/microcrescents.

Adolescent↗
PubMed1988

[Hyperuricemia as a risk factor of nephropathy in gout].

Among 196 patients with primary gout examined in hospital or earlier stable or transient hyperuricemia was noted in 160 (81.6%). These patients were entered into the study group. The control group included 36 persons in whom the level of blood uric acid did not exceed normal values. The familial pattern of disease was established in the patients of the study group. Urolithic, proteinuric and hypertensive types of nephropathy as well as chronic renal insufficiency were more frequently observed in hyperuricemia patients. Alongside with severe tubular, interstitial and vascular changes, glomeruli in the form of mesangioproliferative or mesangiocapillary glomerulonephritis were regularly involved in the pathological process. In the rest of the patients vascular lesions were less marked and less frequent, renal glomerular changes reminded the picture of mesangioproliferative glomerulonephritis only; urolithiasis in them took a more favorable course. Thus, a high level of blood uric acid is one of the risk factors of renal affection in gout determining in many ways prognosis of disease.

Adult↗
PubMed1987

[Primary mesangiocapillary glomerulonephritis].

The etiology and clinical and histologic features of primary mesangiocapillary glomerulonephritis (PMCGN) are reviewed, as are its management and prognosis. The problem of PMCGN, which is a well-defined disease entity, is shown to be one of major concern for nephrology today. A number of issues concerning the etiology, natural history, morphology, and treatment of this disease remain unresolved or require closer study.

Adult↗
PubMed1987

[Substantiation and effectiveness of the use of purine antagonists in gouty nephropathy].

Similarity of the morphological picture of gouty nephropathy and primary glomerulonephritides in which purine antagonists turned out to be effective, a positive effect of azathioprine (Az) and 6-mercaptopurine (MP) on purine metabolism, and changes in immunity indices revealed in gout (hyperproduction of immunoglobulins and circulating immune complexes) necessitates the use of antimetabolites in combined therapy of gout patients with proteinuric and latent types of nephropathy. A prolonged use of Az and MP at a daily dose of 50-100 mg often leads to the recovery or improvement of lowered renal function, disappearance of the urinary syndrome, and suppression of hyperuricemia. Uricosuppressors without purine antagonists produce a weaker effect on the course of a renal process, and the treatment of such patients without the use of basic drugs has proved to be utterly ineffective. Strict control over Az and MP therapy makes side-effects of the drugs rare, and they can be easily done away with after reducing a drug dose.

Adult↗